Decision to test 3 companies’ vaccine production capability in country
Published: 01:28 PM, 6 May 2021 Updated: 01:30 PM, 6 May 2021
It has been decided to initially test the capabilities of three pharmaceutical companies for the production of coronavirus vaccine in the country. These companies are – Incepta Pharmaceuticals, Healthcare Pharmaceuticals and Popular Pharmaceuticals.
The decision was taken at an Inter-ministerial Advisory Committee on Coronavirus Vaccine Collection and Distribution at its first meeting on Wednesday.
At the meeting, the committee asked the Directorate General of Drug Administration (DGDA) to make a final recommendation by evaluating the production capacity of the three companies through scoring.
According to sources, the meeting called for the immediate supply of the Russian vaccine Sputnik-V to the Ministry of Foreign Affairs, including possible observations based on expert opinions, and finalizing the supply agreement through bargaining.
For the time being, it was decided to collect 60 million vaccines (5 million doses per month) quickly and to compare the analysis from a multidimensional source instead of a single source.